Lacutamab | Innate Pharma

Innate Pharma reports IPH4102 results in advanced Cutaneous T Cell Lymphoma (CTCL)

September 29, 2018

Oral presentation on data with longer follow-up of dose escalation patients and new data from cohort expansion in the Phase I study at the EORTC CLTF 2018 Meeting IPH4102 showed encouraging clinical...

Innate Pharma Hosts R&D Day Today in London

March 8, 2018

Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...

Final results of the dose-escalation part from the phase I trial evaluating IPH4102 in patients with advanced cutaneous T-cell lymphomas presented at the EORTC CLTF meeting

October 16, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that final results of the dose-escalation part of the ongoing Phase I study investigating IPH4102 in patients with...

Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102

June 15, 2017

Oral presentation on the dose-escalation part of a Phase I trial at the International Conference on Malignant Lymphoma (ICML) in Lugano; IPH4102 was evaluated in elderly and heavily pretreated...

IPH4102: Completion of the dose escalation part of the Phase I trial - Data to be presented at International Conference on Malignant Lymphoma in June 2017 in Lugano

May 22, 2017

Complete safety results and updated clinical activity data will be presented at the ICML 2017 in Lugano in June; Preparation for cohort expansion part is ongoing. Innate Pharma SA (the “Company” -...

Encouraging initial results for IPH4102 presented at the Third World Congress of Cutaneous Lymphomas

October 26, 2016

Preliminary data from the dose-escalation part of an ongoing Phase I trial in elderly and heavily pretreated patients including a majority of patients with Sezary syndrome; IPH4102 shows good safety...

Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data

November 10, 2016

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the Company will host a conference call for institutional investors and sell-side analysts to discuss recent...

Further clinical data for lirilumab and IPH4102 presented at ASH annual meeting reinforcing confidence in our programs

December 5, 2016

Enrollment in the first-in-human trial of IPH4102 in relapsed/refractory cutaneaous T-cell lymphomas (CTCL) is proceeding with no dose-limiting toxicities to date; Dose level 9 out of 10 is currently...

Publications & Presentations

We are proud to contribute to the scientific advancements on innate immunity and NK cells. Since our founding in 1999, our researchers have been published in several high impact factor journals, highlighting our expertise in NK cell modulation and commitment to the highest quality science.

Read more about Publications & Presentations

Preliminary safety and clinical activity results for IPH4102 to be presented at the Third World Congress of Cutaneous Lymphomas

October 13, 2016

Preliminary results from the dose-escalation part of Phase I study in patients with relapsed/refractory cutaneous T-cell lymphomas Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH)...

Subscribe to Lacutamab

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers